NLS Pharmaceutics NLSP Stock
NLS Pharmaceutics Price Chart
NLS Pharmaceutics NLSP Financial and Trading Overview
| NLS Pharmaceutics stock price | 1.5 USD |
| Previous Close | 0.92 USD |
| Open | 0.93 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 0.88 - 0.97 USD |
| 52 Week Range | 0.33 - 1.88 USD |
| Volume | 185.19K USD |
| Avg. Volume | 40.79K USD |
| Market Cap | 31.46M USD |
| Beta (5Y Monthly) | -0.818672 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.83 USD |
NLSP Valuation Measures
| Enterprise Value | 20.72M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.7636364 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 9.60396 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.34 |
Trading Information
NLS Pharmaceutics Stock Price History
| Beta (5Y Monthly) | -0.818672 |
| 52-Week Change | 71.98% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.88 USD |
| 52 Week Low | 0.33 USD |
| 50-Day Moving Average | 1.23 USD |
| 200-Day Moving Average | 1.1 USD |
NLSP Share Statistics
| Avg. Volume (3 month) | 40.79K USD |
| Avg. Daily Volume (10-Days) | 44.63K USD |
| Shares Outstanding | 32.43M |
| Float | 14.18M |
| Short Ratio | 2.6 |
| % Held by Insiders | 27.14% |
| % Held by Institutions | 18.16% |
| Shares Short | 99.92K |
| Short % of Float | 0.47% |
| Short % of Shares Outstanding | 0.30% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -128.66% |
| Return on Equity (ttm) | -862.91% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -15470956 USD |
| Net Income Avi to Common (ttm) | -16495680 USD |
| Diluted EPS (ttm) | -0.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.95M USD |
| Total Cash Per Share (mrq) | 0.28 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.752 |
| Book Value Per Share (mrq) | 0.101 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13879371 USD |
| Levered Free Cash Flow (ttm) | -8688166 USD |
Profile of NLS Pharmaceutics
| Country | United States |
| State | N/A |
| City | Zurich |
| Address | The Circle 6 |
| ZIP | 8058 |
| Phone | 41 44 512 21 50 |
| Website | https://nlspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Q&A For NLS Pharmaceutics Stock
What is a current NLSP stock price?
NLS Pharmaceutics NLSP stock price today per share is 1.5 USD.
How to purchase NLS Pharmaceutics stock?
You can buy NLSP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NLS Pharmaceutics?
The stock symbol or ticker of NLS Pharmaceutics is NLSP.
Which industry does the NLS Pharmaceutics company belong to?
The NLS Pharmaceutics industry is Biotechnology.
How many shares does NLS Pharmaceutics have in circulation?
The max supply of NLS Pharmaceutics shares is 4.06M.
What is NLS Pharmaceutics Price to Earnings Ratio (PE Ratio)?
NLS Pharmaceutics PE Ratio is now.
What was NLS Pharmaceutics earnings per share over the trailing 12 months (TTM)?
NLS Pharmaceutics EPS is -6.74 USD over the trailing 12 months.
Which sector does the NLS Pharmaceutics company belong to?
The NLS Pharmaceutics sector is Healthcare.
NLS Pharmaceutics NLSP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}